Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine–induced injury in human internal thoracic artery

Chao Xuan, MPhil,a Feng-Jun Chang, MD,b Xiao-Cheng Liu, MD,a Xiao-Yan Bai, MD,a Xiao-Long Liao, MD,b Guo-Wei He, MD, PhD, DSc,c and Jing-Song Ou, MD, PhD, FCCPb

**Objectives:** Endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine is a cardiovascular risk factor that is elevated in patients with coronary artery disease. We hypothesized that novel endothelial nitric oxide synthase enhancer AVE3085 might improve the endothelial function altered by asymmetric dimethylarginine in the human internal thoracic artery.

**Methods:** Cumulative concentration-relaxation curves to acetylcholine (−11 to −5 log mol/L) were established in left internal thoracic artery rings (n = 65) from 27 patients undergoing coronary artery bypass grafting in precontraction induced by U46619 (−8 log mol/L) in the absence or presence of asymmetric dimethylarginine (100 μmol/L) or AVE3085 (30 μmol/L). Protein expressions of endothelial nitric oxide synthase and levels of superoxide anion production were detected.

**Results:** Maximal relaxation induced by acetylcholine was significantly attenuated by asymmetric dimethylarginine (12.7% ± 2.3% vs 35.3% ± 5.0% in control; P < .05) and significantly restored by AVE3085 (23.4% ± 2.8%; P < .05). AVE3085 also markedly restored endothelial nitric oxide synthase expression (0.29 ± 0.008; P = .012) reduced by asymmetric dimethylarginine (0.05 ± 0.04 vs 0.36 ± 0.03 in control; P = .014). Increased superoxide anion production by asymmetric dimethylarginine (2.97 ± 0.25 vs 0.51 ± 0.10 relative light units/[s/mg]) in control; P < .05) was inhibited by AVE3805 (0.62 ± 0.104 relative light units/[s/mg]; P < .05).

**Conclusions:** AVE3085 may restore endothelium-dependent relaxation reduced by asymmetric dimethylarginine through upregulation of endothelial nitric oxide synthase expression and inhibition of production of superoxide anion in human internal thoracic artery. These findings provide new insights into endothelial protection of coronary bypass grafting vessels to improve long-term patency of grafts. (J Thorac Cardiovasc Surg 2012;144:697-703)

Asymmetric dimethylarginine (ADMA) is produced in human cells during proteolysis of methylated nuclear proteins. It acts as an endogenous inhibitor of endothelial nitric oxide synthase (eNOS) by competing with L-arginine, and this in turn causes endothelial dysfunction. Alternatively, ADMA may uncouple eNOS, leading not only to the loss of nitric oxide but also to increased superoxide production in the vascular endothelium and induced apoptosis of endothelial cells. Superoxide anion generation also can scavenge nitric oxide to impair vascular function and inhibit vasodilation. The occurrence of cardiovascular end points in high-risk patients has been found to be directly and independently associated with elevated ADMA concentrations in patients with coronary artery disease, diabetes mellitus, and chronic heart failure. Recently, 2 new small–molecular weight compounds (AVE9448 and AVE3085) were developed to increase endothelial nitric oxide production by simultaneous upregulation of eNOS expression and reversal of eNOS uncoupling. It has been demonstrated that impaired eNOS production is enhanced by AVE3085 treatment in the hind limb of severely diabetic animals and that treatment with AVE3085 significantly increases eNOS messenger RNA and protein levels in cardiac tissue. Further, we have recently demonstrated that use of AVE3085 protects porcine coronary endothelium from ischemia–reperfusion or hypoxia–reoxygenation injury and
ET/BS

LDL cholesterol (mmol/L, mean ± SEM) 3.70 ± 0.37

Dopamine* (no.) 1 (3.7) 100%

HDL cholesterol (mmol/L, mean ± SEM) 1.08 ± 0.25

Triglycerides (mmol/L, mean ± SEM) 3.0 ± 0.86

Nitroglycerin* (no.) 27 (100%)

Dopamine* (no.) 1 (3.7)

restores impaired endothelial function in a hypertensive model.10,11 In addition, AVE3085 has been shown to ameliorate endothelial dysfunction in db/db mice through increased nitric oxide bioavailability, which reduces oxidative stress in the vascular wall.12 This study was therefore designed to test the hypothesis that ADMA has detrimental effects on the endothelial function in the human internal thoracic artery, including both decreased nitric oxide-mediated relaxation and increased superoxide anion production, and that AVE3085 could restore these functions.

MATERIALS AND METHODS

Vessel Preparation

The discarded left internal thoracic artery (LITA) segments from patients undergoing coronary artery bypass grafting (n = 27; Table 1) were immediately collected for transfer to the laboratory. Approval to use the discarded human vessel was given by the ethics committee (institutional review board) of TEDA International Cardiovascular Hospital, Tianjin, China. During coronary artery bypass grafting with LITA grafts, the LITA was harvested as a full pedicle. The length required for grafting was carefully measured, usually immediately after the dissection of the LITA pedicle. The redundant distal end was trimmed off and immediately placed in a container with oxygenated physiologic salt solution, maintained at 4°C, and transferred to the laboratory within 5 to 10 minutes. The adherent connective tissue was carefully dissected, and the LITA was cut precisely into 3-mm long segments. Organ baths in the myograph were filled with Krebs solution, maintained at 37°C and aerated continuously with a mixture of 95% oxygen and 5% carbon dioxide. The modified Krebs solution had the following composition: sodium ion, 144 mmol/L; potassium ion, 5.9 mmol/L; calcium ion, 2.5 mmol/L; magnesium ion, 1.2 mmol/L; chloride ion, 128.7 mmol/L; hydrogen carbonate ion, 25 mmol/L; sulfate ion, 1.2 mmol/L; dihydrogen phosphate ion, 1.2 mmol/L; and glucose, 11 mmol/L.

Myograph Techniques

Human LITA ring segments were suspended on wire hooks in a 6-mL bath on a myograph modified for large vessel studies (model 610M; DMT Company, Aarhus, Denmark). Each ring segment resting unstretched on the wire hooks was equilibrated in Krebs solution for at least 60 minutes.

Normalization

A technique described previously in detail elsewhere was used in this study.13 Briefly, each ring segment was stretched up in progressive steps every minute to determine the individual length–tension curve. A computer iterative fitting program (Myodaq and Myodata version 2.01; Maastricht University, Maastricht, The Netherlands) was used to determine the exponential curve pressure and the internal diameter. At the end of each step, the internal diameter (in micrometers) and the corresponding wall tension (in millinewtons per square millimeter) were recorded. When the transmural pressure on the rings reached 100 mm Hg, as determined according to the length–tension curves, the stretching procedure was stopped, and the rings were released to 90% of their internal circumference at 100 mm Hg.13,14 This degree of passive tension was then maintained throughout the experiment.

Western Blot Analysis of eNOS

LITA samples were homogenized in lysis buffer (KeyGEN, Inc, Nanjing, China), and the lysates were incubated in ice for 1 hour followed by 10 minutes of centrifugation at 10,000 rpm. After the sample was heated at 100°C for 5 minutes to denature it, 120 μg protein for each sample was separated by 8% polyacrylamide gel electrophoresis (Page Gel, Inc, San Diego, Calif) together with the prestained protein ladder (MBI Fermentas, Inc, Glen Burnie, Md). The proteins were transferred electrophoretically to the polyvinylidene fluoride membrane (Millipore, Billerica, Mass). The membrane was blocked with blocking buffer (tris-buffered saline solution, 0.1% polysorbate 20, 5% nonfat dry milk) at a dilution of 1:1,000; Cell Signaling Technology, Inc, Boulder, Colo) at a dilution of 1:5000 was added the next day. Finally, blots were developed with an enhanced chemiluminescence detection system (Amersham Pharmacia ECL reagents; GE Healthcare Biosciences, Piscataway, NJ) and exposed to x-ray films. The protein bands were quantified with QuantityOne software (Bio-Rad Laboratories, Inc, Hercules, Calif), normalized by glyceraldehyde 3-phosphate dehydrogenase, and expressed as multiples of control.

Superoxide Anion Measurement in Human Thoracic Artery

LITA vessels were gently cut open longitudinally to expose the endothelial surface and incubated in oxygenated Krebs buffer with drugs at 37°C for 2 hours before measurement. The segments were then rinsed briefly in Krebs–4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and maintained at 37°C for 30 minutes. Lucigenin-enhanced chemiluminescence

<table>
<thead>
<tr>
<th>Age (y, mean ± SEM)</th>
<th>60.6 ± 5.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (no.)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>11 (40.7%)</td>
</tr>
<tr>
<td>Male</td>
<td>16 (59.3%)</td>
</tr>
<tr>
<td>Smoking habit (no.)</td>
<td>13 (48.1%)</td>
</tr>
<tr>
<td>Body mass index (kg/m², mean ± SEM)</td>
<td>26.11 ± 3.40</td>
</tr>
<tr>
<td>Blood pressure (mm Hg, mean ± SEM)</td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>132.7 ± 16.7</td>
</tr>
<tr>
<td>Diastolic</td>
<td>77.2 ± 11.9</td>
</tr>
<tr>
<td>Diabetes mellitus (no.)</td>
<td>19 (70.4%)</td>
</tr>
<tr>
<td>Unstable angina (no.)</td>
<td>22 (81.3%)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L, mean ± SEM)</td>
<td>4.72 ± 1.03</td>
</tr>
<tr>
<td>Triglycerides (mmol/L, mean ± SEM)</td>
<td>1.74 ± 0.95</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L, mean ± SEM)</td>
<td>1.08 ± 0.25</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L, mean ± SEM)</td>
<td>3.0 ± 0.86</td>
</tr>
<tr>
<td>Nitroglycerin* (no.)</td>
<td>27 (100%)</td>
</tr>
<tr>
<td>Dopamine* (no.)</td>
<td>1 (3.7%)</td>
</tr>
</tbody>
</table>

HDL, High-density lipoprotein; LDL, low-density lipoprotein. *Use of vasodilators or vasoconstrictors during the harvesting of the left internal thoracic artery.
was measured in each segment with low-concentration lucigenin (5 μmol/L). Time-based reading of the fluorescence microplate reader was recorded by softMax pro v5.0.1 software. The luminescence in relative light units (RLU) per second for each sample was averaged between 5 and 10 minutes. Values of blank chambers that contained the same reagents were recorded as background, and the background values were subtracted from those of the corresponding vessel samples. Data were normalized to vessel dry weight and were represented as RLU per second per milligram dry weight.

**Experimental Protocol**

Ring segments were precontracted with U46619 at a concentration of 10^8 mol/L. Our previous studies showed that U46619 at 10^8 mol/L induced 60% to 80% of maximal contractile responses in the LITA ring segments.13,14

**Effects of ADMA and AVE3085 on Acetylcholine-Induced Endothelium-Dependent Relaxation**

The LITA ring segments from the same patient were allocated randomly into 3 groups (n = 8 per group). In 1 group, the LITA ring segments were incubated with Krebs solution as a control. In the other 2 groups, the LITA ring segments were incubated with Krebs solution in the presence of ADMA (100 μmol/L) or ADMA (100 μmol/L) with AVE3085 (30 μmol/L, dissolved in dimethyl sulfoxide [DMSO]) for 1 hour before the precontraction was started.

The acetylcholine-induced relaxation in the presence of DMSO (the solvent of AVE3085) was also tested to exclude the effect of the solvent (n = 8 in each group). In 1 group, the LITA segment was incubated with Krebs solution in the presence of ADMA (100 μmol/L), and in the other group, the LITA segments were incubated with Krebs solution in the presence of ADMA (100 μmol/L) plus DMSO for 1 hour before the precontraction was started. The results were then compared with those of the Krebs solution control.

In separate rings (n = 4), the endothelium was mechanically removed by gently rubbing the luminal surface of the ring with small plastic tubing (endothelium-denuded vessels).

Ring segments were precontracted with U46619 (10^8 mol/L). When the contraction reached a stable plateau, acetylcholine (10^{-11} to 10^{-5} mol/L) was applied to a cumulative concentration at an interval between doses to allow the relaxation induced by the previous dose to reach a plateau. The relaxation was expressed as percentage reversal of the U46619-induced precontraction.

**Western Blot Analysis of eNOS**

Immediately after the previously described relaxation study, the LITA segments for control, ADMA, and ADMA with AVE3085 were flash-frozen in liquid nitrogen and stored at −80°C for protein study (n = 8 in each group). The previously mentioned steps for eNOS measurement were then repeated. The total exposure time for the vessel to study of the protein expression was 5.56 ± 0.25 hours.

**Measurement of Superoxide Anion**

The LITA ring segments from the same patient were allocated randomly into 3 groups (n = 7 in each group). After 30 minutes of equilibration of each segment in the organ chamber, the LITA ring segments were incubated with Krebs solution (control) or with Krebs solution in the presence of ADMA (100 μmol/L) or ADMA (100 μmol/L) with AVE3085 (30 μmol/L) for 2 hours. The previously mentioned steps for superoxide anion measurement were then repeated.

**Data Analysis**

Relaxation was expressed as the percentage decrease in isometric force induced by U46619. Mean maximal relaxation (Emax) for each group was calculated from the maximal relaxation of different rings induced by acetylcholine. The effective concentration of acetylcholine that caused 50% of Emax was defined as EC50. The EC50 was determined from each concentration–relaxation curve by a logistic, curve-fitting equation: E = M * (A^k + K). Where E is response, M is maximal relaxation (Emax), A is concentration, K is EC50, and P is the slope parameter. From this fitted equation, the mean EC50 ± SEM was calculated for each group.

All statistical analyses were performed with the SPSS statistical software package (version 10.0; International Business Machines Corp, Armonk, NY). All values are expressed as mean ± SEM. Statistical comparisons of the percentage relaxation under different treatments were performed by 2-way analysis of variance (ANOVA; general linear model) with repeated measures, followed by post hoc Bonferroni test to detect the individual differences. The comparison of the Emax was performed with unpaired t test. EC50, eNOS expression, and superoxide anion were compared by 1-way ANOVA followed by post hoc Bonferroni test. The 95% confidence interval (CI) for difference was also shown when possible; n values refer to number of ring segments from separate patients.

**Drugs**

Acetylcholine and ADMA were purchased from Sigma-Aldrich (St Louis, Mo). U46619 was from Cayman Chemical (Ann Arbor, Mich). AVE3085 was kindly provided by Sanofi-Aventis Deutschland GmbH (Frankfurt, Germany) and dissolved in DMSO. Others were dissolved in distilled water. Stock solutions of U46619 and acetylcholine were kept at −20°C until required.

**RESULTS**

Among the groups of the patients whose LITAs were studied, there were no differences with regard to the clinical characteristics (P > .05 among the groups, details not shown; Table 1).

**Resting Parameters**

The internal diameter of the vessels at an equivalent transmural pressure of 100 mm Hg was 1.82 ± 0.07 mm (n = 44), as determined from the computerized normalization procedure. The resting transmural pressure was 81.8 ± 1.0 mm Hg at 90% of this value. The resting force of the LITA rings was 2.3 ± 0.09 g.

**Effect of ADMA and AVE3085 on Acetylcholine-Induced Relaxation**

The acetylcholine-mediated relaxation was abolished in the endothelium-denuded rings (Figure 1, A). This result shows that the acetylcholine-induced relaxation in our experiments was endothelium dependent (Figure 1, B).

The acetylcholine-mediated relaxation was significantly inhibited in the presence of ADMA (P < 0.001 by 2-way ANOVA). In comparison with ADMA alone, addition of AVE3085 to ADMA significantly increased the acetylcholine-induced relaxation (P = .001 by 2-way ANOVA; Figure 1, B).

Further, the Emax induced by acetylcholine (35.3% ± 5.0% in control; 95% CI 25.1%–45.5%) was significantly reduced in the rings treated with ADMA (12.7% ± 2.3%; 95% CI 8.0%–17.3%; P < .05 by unpaired t test) or ADMA with AVE3085 (23.4% ± 2.8%; 95% CI 17.6%–29.1%; P < .05 by unpaired t test). In addition, in comparison
with ADMA alone, addition of AVE3085 to ADMA significantly increased the E_max induced by acetylcholine (P < .05 by unpaired t-test).

The EC_{50} was not significantly different between the ADMA and ADMA with DMSO groups (ADMA, −7.04 ± 0.30 log mol/L; ADMA with DMSO, −6.57 ± 0.44 log mol/L; P > .05 by 1-way ANOVA).

Protein Expressions of eNOS: Effects of ADMA and AVE3085

Expression of eNOS protein in LITA segments was significantly decreased after incubation with ADMA (0.05 ± 0.04 vs 0.36 ± 0.03 in control; P = .014 by 1-way ANOVA). Addition of AVE3085 to ADMA markedly increased the expression level of eNOS (0.29 ± 0.08; P = .012 vs ADMA alone by 1-way ANOVA), although there was still a difference between ADMA with AVE3085 and control (0.29 ± 0.08 vs 0.36 ± 0.03 in control; P = .026 by 1-way ANOVA; Figure 3).

Superoxide Anion Production: Effects of ADMA and AVE3085

As shown in Figure 4, superoxide anion generation in LITA segments was low under basal conditions (0.51 ± 0.102 RLU/[s/mg]). ADMA dramatically increased superoxide anion production (2.97 ± 0.25 RLU/[s/mg]; P < .05 vs control by 1-way ANOVA). Addition of AVE3085 significantly inhibited the ADMA-induced superoxide anion generation (0.62 ± 0.104 RLU/[s/mg]; P < .05 vs ADMA group by 1-way ANOVA).

DISCUSSION

This study has demonstrated in human internal thoracic artery samples that (1) increased ADMA levels directly alter the E_max induced by acetylcholine (14.4% ± 1.5%, 95% CI 11.3%–17.5%; P > .05 by unpaired t-test).

The EC_{50} was not significantly different between the ADMA and ADMA with DMSO groups (ADMA, −7.04 ± 0.30 log mol/L; ADMA with DMSO, −6.57 ± 0.44 log mol/L; P > .05 by 1-way ANOVA).
endothelial dysfunction by downregulating protein expression of eNOS and by increasing superoxide anion production and (2) these 2 mechanisms damaging the endothelial function may be partially reversed by the eNOS enhancer AVE3085. Because endothelial function is one of the major factors influencing the long-term patency of coronary artery bypass grafting conduits, these findings provide new insights in the protection of the endothelium of coronary bypass grafting conduits to improve the long-term patency of these grafts.

Nitric oxide has been widely regarded as the major mediator of endothelium-dependent vasodilation and plays a crucial role in the endothelium-mediated regulation of vascular homeostasis. It also regulates the vascular structure and cell–cell interactions in blood vessels. A relatively newly found and intriguing mechanism that leads to a reduction in nitric oxide is ADMA, an endogenous competitive inhibitor of eNOS that has been linked to endothelial dysfunction. Importantly, it has been demonstrated that elevated ADMA concentrations are found in patients with coronary artery disease and other related diseases, such as diabetes mellitus and chronic heart failure.

It has been reported that ADMA induces the production of reactive oxygen species in endothelial cells, which may contribute to the senescence and apoptotic death of endothelial cells. It is now clear that ADMA affects superoxide anion production by uncoupling of eNOS and other eNOS-independent pathways. In addition, superoxide anion production can attack the eNOS directly and induce dissociation of eNOS dimer into monomer. One study has suggested that the decrease in nitric oxide production may be related to a reduction of eNOS expression by elevation of ADMA level in cultured endothelial cells.

On the basis of these findings, the role of ADMA in the nitric oxide-related endothelial function of the human LITA vessels used as coronary artery bypass grafts is an important issue in the treatment of coronary artery disease. ADMA has been shown to be independently associated with maximum vasorelaxation in response to acetylcholine in saphenous veins, but whether ADMA affects the endothelium-dependent relaxation in human arteries is still unknown. In this study, we found that the acetylcholine-induced, endothelium-dependent relaxation was significantly reduced by incubation of the human LITA with ADMA. This finding clearly demonstrates that ADMA plays a role in reducing nitric oxide–mediated relaxation in human arteries.

As a novel small–molecular weight compound, AVE3085 increases endothelial nitric oxide production by the simultaneous upregulation of eNOS expression and reversal of eNOS uncoupling. Previous studies have indicated that long-term treatment with AVE3085 significantly increases eNOS messenger RNA and protein levels in the cardiac tissues of male Sprague-Dawley rats and male Dahl salt-sensitive rats. Further, we have recently demonstrated that use of AVE3085 protects porcine coronary endothelium from ischemia–reperfusion injury and restores impaired endothelial function in a hypertensive model by significantly increasing the eNOS expressions of endothelial cells. In addition, AVE3085 has been shown to ameliorate endothelial dysfunction in db/db mice through increased nitric oxide bioavailability, which reduces oxidative stress in the vascular wall.

Interestingly, we found that the expression of eNOS was downregulated in human LITA specimens when they were incubated with asymmetric dimethylarginine (ADMA) in Krebs solution with or without the addition of AVE3085 (AVE) or for the same period in Krebs solution alone (control). Date are shown as mean ± SEM. Asterisk indicates $P < .05$ versus control group; hatch mark indicates $P < .05$ versus asymmetric dimethylarginine group; $n = 8$, 1-way analysis of variance. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.

**FIGURE 3.** Protein expression of endothelial nitric oxide synthase (eNOS) in human left internal thoracic artery rings. Arterial rings were incubated with asymmetric dimethylarginine (ADMA) in Krebs solution with or without the addition of AVE3085 (AVE) or for the same period in Krebs solution alone (control). Date are shown as mean ± SEM. Asterisk indicates $P < .05$ versus control group; hatch mark indicates $P < .05$ versus asymmetric dimethylarginine group; $n = 8$, 1-way analysis of variance. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.

**FIGURE 4.** Superoxide production in human left internal thoracic artery rings. Vascular rings were incubated with asymmetric dimethylarginine (ADMA, 100 μmol/L) in Krebs solution with or without the addition of AVE3085 (AVE, 30 μmol/L) or in Krebs solution alone (control). Data are shown as mean ± SEM. Asterisk indicates $P < .05$ versus control group; hatch mark indicates $P < .05$ versus asymmetric dimethylarginine group; $n = 7$, 1-way analysis of variance. RLU, Relative light units.
incubated with AMDA and that the addition of AVE3085 significantly increased the eNOS protein level. These findings demonstrate that the reduction of the relaxation may be associated with the downregulation of eNOS, as Jiang and associates suggested that the decrease of the nitric oxide production may be related to reduction of eNOS expression by elevation of ADMA level in cultured endothelial cells.

It is well known that superoxide anion impairs vascular function. Recent studies showed that ADMA, an endogenous inhibitor of eNOS, uncoupled eNOS activity to generate superoxide anion by inhibiting heat shock protein 90 associated with eNOS. In accordance with other reports, we found in this study that ADMA could uncouple eNOS activity to increase superoxide anion generation in cultured internal thoracic arteries. In fact, we found that AVE3805 inhibited ADMA-induced superoxide anion generation. Our findings indicate that AVE3805 may be able to maintain the eNOS coupling activity to produce nitric oxide in the human artery, which supports the potential use of AVE3805 to protect vascular endothelial function in human disease.

In this study, we tested the hypothesis that the newly developed eNOS enhancer AVE3085 could play a role in the restoration of the downregulated eNOS and therefore restore the acetylcholine-induced, endothelium-dependent relaxation to a certain extent. The results support this hypothesis, because incubation of LITA ring segments in AVE3085 (30 μmol/L) significantly improved the acetylcholine-induced relaxation that was reduced by ADMA alone. This study also demonstrated that such restoration of the endothelium-dependent relaxation is associated with eNOS and superoxide anion changes.

**Study Limitations**

This study is an in vitro experimental investigation at the tissue (vascular) and molecular levels. Any in vivo protective effect of AVE3085 on the endothelial function damaged by ADMA in the LITA and its potential clinical impact on the long-term patency of the graft remain to be defined.

**Clinical Implications**

Use of eNOS enhancers to restore the reduced nitric oxide–related endothelial function is a new therapeutic strategy that may have clinical implications in a number of clinical situations associated with endothelial dysfunction, such as diabetes, hypertension, and ischemia–reperfusion injury in coronary artery disease, cardiac surgery, or organ transplants. This study emphasizes that the use of eNOS enhancers may improve endothelial function in the human arteries used as grafts in coronary artery bypass grafting and thus supports the trial of those new drugs as a therapeutic strategy for the listed pathologic conditions.

**CONCLUSIONS**

In conclusion, the results of our study in the human LITA suggest that increased ADMA levels directly cause endothelial dysfunction by downregulating protein expression of eNOS and by increasing superoxide production. These mechanisms of endothelial dysfunction may be partially reversed by means of the eNOS enhancer AVE3085. These findings provide new insights into the protection of the endothelium of the coronary artery bypass grafting conduit to improve the long-term patency of the grafts.

The assistance of the surgical team (Dr Jing Wen-Bin) and nurses (En-Jie Yu and the team members) in the Cardiac Operating Theater, TEDA International Cardiovascular Hospital, is gratefully acknowledged.

**References**


